#39 – Part One: Has Atai Life Sciences Taken the Psychedelic Throne From MAPS?
Brian Normand, David Nickles, and Russell Hausfeld are joined by new team member, Sarvesh Ramprakash, to discuss Atai Life Sciences’ recent IPO on Nasdaq. They also discuss and provide updates on Russell’s previous 2020 report exploring how the introduction of for-profit psychedelic pharmaceutical c
Apple
Podcasts
Google Podcasts
Spotify
Stitcher
Radio Public
Deezer
RSS
Brian Normand, David Nickles, and Russell Hausfeld are joined by new team member, Sarvesh Ramprakash, to discuss Atai Life Sciences’ recent IPO on Nasdaq. They also discuss and provide updates on Russell’s previous 2020 report exploring how the introduction of for-profit psychedelic pharmaceutical corporations has shifted capital away from non-profits.
Co-hosts: Brian Normand, David Nickles, Russell Hausfeld, Sarvesh Ramprakash. Editor: Matt Payne